CS2000
SARS-CoV-2 (COVID-19) Inhibitors Screening Kit
Based on SPIKE - ACE2 Binding Assay, Colorimetric, sufficient for 200 tests
동의어(들):
ACE2, COVID-19, S protein, SARS-CoV-2, Spike protein
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
| 팩 크기/SKU | 재고 정보 | 가격 (VAT 별도) |
|---|---|---|
1 kit | 예상 입고일2026년 10월 12일재고 수량 조회Seoul Warehouse South Korea | ₩1,632,729 |
제품정보 (DICE 배송 시 비용 별도)
NACRES:
NA.84
UNSPSC Code:
12352200
₩1,632,729
예상 입고일2026년 10월 12일세부사항
General description
designed to simplify the identification and characterization of SARS-CoV-2 inhibitors.
Application
The SARS-CoV-2 Inhibitors Screening Kit is a convenient tool, designed to simplify the identification and characterization of SARS-CoV-2 inhibitors.The crutial interaction between the SARS-CoV-2 and human cells accrues through the protein-protein interaction of human receptor ACE2 and viral protein Spike – S protein. The receptor binding domain (RBD) of S protein is the domain that specifically binds to ACE2. Our SARS-CoV-2 Inhibitors Screening Kit includes both human ACE protein and viral RBD of S protein. The kit is based on a colorimetric ELISA, where biotinylated ACE2 (ACE2-biotin) and Extravidin®-peroxidase are used to detect the ACE2:RBD interaction. One molecule of Extravidin® binds four molecules of biotin by a non-covalent interaction that is essentially irreversible. Binding visualization is achieved by using o-Phenylenediamine dihydrochloride (OPD), a peroxidase substrate with absorbance at 450 nm.
Inhibitors and neutralizing antibodies against RBD that interfere with the ACE2:RBD interaction will result in reduced colorimetric signal.
Inhibitors and neutralizing antibodies against RBD that interfere with the ACE2:RBD interaction will result in reduced colorimetric signal.
Biochem/physiol Actions
SARS-CoV-2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to Coronaviridae (CoVs) - a large family of viruses that usually cause mild to moderate upper-respiratory tract diseases.1 CoVs are single-stranded RNA viruses. They have a high mutation rate and are therefore highly diverse.1 Their hosts include human and non-human mammals, as well as birds.1
SARS-CoV-2 infects cells which express angiotensin converting enzyme 2 (ACE2).2 ACE2 binds to the viral envelope-associated spike (S) protein as a cellular receptor, following proteolytic cleavage of both S and ACE2 by serine proteases.3 S protein is believed to be the target of neutralizing antibodies because it is the main trans-membrane glycoprotein responsible for receptor-binding and virion entry.4
The S protein is a trimeric protein. During the binding to ACE2, S protein undergoes a substantial structural rearrangement to facilitate the fusion of the viral membrane with the host cell membrane.5 The receptor binding domain (RBD) of S protein is the domain that specifically binds to ACE2. RBD is the major target for neutralizing antibodies for coronaviruses6, and anti-RBD antibodies likely correlate with virus neutralization.7
SARS-CoV-2 infects cells which express angiotensin converting enzyme 2 (ACE2).2 ACE2 binds to the viral envelope-associated spike (S) protein as a cellular receptor, following proteolytic cleavage of both S and ACE2 by serine proteases.3 S protein is believed to be the target of neutralizing antibodies because it is the main trans-membrane glycoprotein responsible for receptor-binding and virion entry.4
The S protein is a trimeric protein. During the binding to ACE2, S protein undergoes a substantial structural rearrangement to facilitate the fusion of the viral membrane with the host cell membrane.5 The receptor binding domain (RBD) of S protein is the domain that specifically binds to ACE2. RBD is the major target for neutralizing antibodies for coronaviruses6, and anti-RBD antibodies likely correlate with virus neutralization.7
Features and Benefits
Our SARS-CoV-2 Inhibitors Screening Kit will support your research, enabling to screen and discover inhibitors as potential drugs for COVID-19
Supportive calculator (Click here to download a calculator excel file)
Legal Information
ExtrAvidin is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 2 - Carc. 2 - Eye Dam. 1 - Muta. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
저장 등급
10 - Combustible liquids
wgk
WGK 3